Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Zevra Therapeutics, Inc. Common Stock

ZVRA

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Last trade $9.25
Day change $0.00 (0.00%)
Day range $9.04 – $9.34
Volume 407,404
Market cap $550M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$550.42M
Price / earnings
7.16×
Price / book
2.3×
Price / sales
3.72×
EV / sales
2.95×
EV / EBITDA
-40.57×

Profitability

Earnings per share
$1.29
Return on assets
24.51%
Return on equity
32.17%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.03×
Current ratio
5.46×
Quick ratio
5.38×
Cash ratio
2.95×

Cash flow

Price / cash flow
14.21×
Price / free cash flow
14.38×
Free cash flow
$38.28M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ZVRA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$37.76M$39.66M$36.22M$34.13M$26.06M$25.88M$20.4M$12.04M
Cost of revenue$1.79M$1.53M$1.9M$1.52M$1.24M$12.38M$1.35M$1.37M
Gross profit$35.96M$38.14M$34.32M$32.61M$24.83M$13.5M$19.06M$10.68M
Selling, general and administrative$19.13M$16.56M$20.78M$20.35M$16.94M$20.78M$19.55M$16.13M
Research and development$4.94M$4.49M$4.39M$2.62M$3.43M$3.43M$3.26M$8.35M
Total operating expenses$24.38M$21.36M$25.49M$23.29M$20.68M$84.54M$24.42M$26.09M
Operating income$11.58M$16.78M$8.83M$9.32M$4.14M-$71.04M-$5.36M-$15.42M
Interest expense$0$0-$1.71M-$1.95M-$2.05M-$2.01M-$1.97M-$2.19M
Income before taxes$19.72M$12.79M$44.8M$12.67M-$977K$76.91M-$1.92M-$20.37M
Income taxes$510K$4.04M$6.91M$501K-$433K$2.2M$1.18M$15.37M
Net income$19.21M$8.75M$37.89M$12.17M-$544K$74.71M-$3.1M-$35.74M
Net income attributable to common shareholders$18.42M$8.39M$37.89M$12.17M-$544K$67.91M-$3.1M-$35.74M
EBITDA$11.96M$17.14M$9.2M-$49.03M$4.54M-$10.68M-$3.71M-$13.77M
Basic earnings per share$0.31$0.14$0.62$0.22-$0.01$1.24-$0.06-$0.67
Diluted earnings per share$0.26$0.14$0.60$0.19-$0.01$1.21-$0.06-$0.67

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Wall Street Analysts Believe Zevra Therapeutics (ZVRA) Could Rally 117.86%: Here's is How to Trade

Zevra Therapeutics (ZVRA) has a mean analyst price target of $25.25, suggesting 117.9% upside potential from its current $11.59 price. The stock has received a Zacks Rank #2 (Buy) rating, supported by strong earnings estimate revisions with a 21.8% increase over the past month. However, the article cautions that price targets should not be the sole basis for investment decisions, as analysts often set overly optimistic targets.

Zacks Investment Research

Zevra Therapeutics (ZVRA) Q3 Earnings and Revenues Beat Estimates

Zevra Therapeutics reported Q3 2026 earnings of $0.18 per share, beating consensus estimates of $0.14, with revenues of $37.76 million exceeding expectations by 2.77%. The company has outperformed market estimates in four consecutive quarters. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. Cronos Group is expected to report Q3 results on November 5, with projected earnings of $0.03 per share, down 57.1% year-over-year, though revenues are expected to grow 30.6%.

GlobeNewswire Inc.

Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium

Zevra Therapeutics announced the presentation of long-term real-world data on MIPLYFFA (arimoclomol) for treating Niemann-Pick disease type C at the 2026 SSIEM Annual Symposium. Data from U.S. and German early access programs demonstrate sustained disease stabilization over up to 8 years with a consistent safety profile across diverse patient populations, including adults and children. The pivotal trial showed a 65% reduction in disease progression compared to placebo.

GlobeNewswire Inc.

Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union

Zevra Therapeutics announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the Marketing Authorization Application for arimoclomol to treat Niemann-Pick disease type C. The company plans to request a re-examination of the decision and continues supporting patient access through its Expanded Access Program.

GlobeNewswire Inc.

XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements

XOMA Royalty Corporation reported over $50 million in cash receipts for 2025, with royalties up 68% year-over-year. The company added 22 assets to its portfolio, completed seven acquisitions generating $11.7 million in non-dilutive capital, and repurchased 648,048 shares for $16 million. Key 2026 catalysts include Phase 2b/3 data readouts and potential EMA regulatory decisions on commercial assets OJEMDA and MIPLYFFA.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.